TNFSF10 and renal carcinoma: Our results revealed that TBMS-1 (5 μM) or TRAIL (50 ng/mL) monotherapy had no effect on apoptosis in human renal carcinoma Caki, colon carcinoma HCT116, lung carcinoma A549, and cervical carcinoma HeLa cells (Figure 1A).